Catherine Schulte
Stock Analyst at Baird
(0.52)
# 1652
Out of 5,291 analysts
131
Total ratings
50.50%
Success rate
9.80%
Average return
Main Sectors:
Top Industries:
Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
Agilent Technologies | Maintains: Outperform | 161 159 | 116.29 | 36.73% | 15 | Feb 27, 2025 | |
Maravai LifeSciences | Downgrades: Neutral | 9 3 | 2.29 | 31% | 5 | Feb 26, 2025 | |
Bio-Techne | Downgrades: Neutral | 88 68 | 58.37 | 16.5% | 9 | Feb 19, 2025 | |
Qiagen | Downgrades: Neutral | 52 42 | 39.64 | 5.95% | 3 | Feb 19, 2025 | |
Mettler-Toledo Intl | Maintains: Neutral | 1362 1369 | 1167.86 | 17.22% | 7 | Feb 10, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 268 258 | 202.41 | 27.46% | 7 | Jan 30, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 70 67 | 43.06 | 55.6% | 13 | Nov 6, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 27 26 | 16.06 | 61.89% | 10 | Oct 28, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 632 622 | 491.77 | 26.48% | 25 | Oct 24, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 182 165 | n/a | n/a | 6 | May 12, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 42 38 | 20.01 | 89.91% | 7 | Mar 1, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 56 33 | 39.49 | -16.43% | 3 | Nov 21, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 4 2 | n/a | n/a | 1 | Jun 3, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 335 281 | 79 | 255.7% | 6 | Sep 22, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 21 | n/a | n/a | 1 | May 26, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 35 29 | n/a | n/a | 5 | Apr 7, 2020 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 208 217 | 363.16 | -40.25% | 7 | Oct 30, 2019 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 17 20 | 139.43 | -85.66% | 1 | Jun 28, 2018 |